Zobrazeno 1 - 10
of 35
pro vyhledávání: '"V. G. Hemming"'
Autor:
Juanita P. Graves, Gary L. Larsen, Joan E. Loader, Giuseppe N. Colasurdo, V. G. Hemming, G. A. Prince
Publikováno v:
American Journal of Physiology-Lung Cellular and Molecular Physiology. 268:L1006-L1011
A dysfunction of the nonadrenergic noncholinergic inhibitory (NANCi) system has been invoked as a possible mechanism underlying or contributing to altered airway function. In the present study we assessed whether human respiratory syncytial virus (HR
Publikováno v:
Journal of Virology. 65:103-111
Human parainfluenza virus 3 replicates well in the noses and lungs of two species of cotton rats, Sigmodon hispidus and Sigmodon fulviventer. Peak viral titers of nearly 10(6) PFU/g are reached 2 days after infection in both tissues, are maintained t
Publikováno v:
Military medicine. 164(10)
To describe the nature of the health care delivered to dependent adolescents throughout the military and compare services provided in adolescent medicine clinics with those provided in other medical departments and clinics.Questionnaires were sent to
Autor:
V G, Hemming
Publikováno v:
Military medicine. 163(4)
At the heart of medical science is the responsibility for investigators and practitioners to use the scientific method to seek and apply new knowledge to better understand the mechanisms, diagnosis, treatment, and prevention of disease. At times it i
Autor:
M G, Ottolini, V G, Hemming
Publikováno v:
Drugs. 54(6)
Though 40 years have passed since its discovery, respiratory syncytial virus (RSV), one of the most ubiquitous viruses known, continues to evade most of our efforts to prevent or treat the clinical disease it causes. Long recognised as the most commo
Autor:
W J, Rodriguez, W C, Gruber, R C, Welliver, J R, Groothuis, E A, Simoes, H C, Meissner, V G, Hemming, C B, Hall, M L, Lepow, A J, Rosas, C, Robertsen, A A, Kramer
Publikováno v:
Pediatrics. 99(3)
To evaluate the efficacy of high-titer intravenous respiratory syncytial virus immune globulin (RSVIG) in the treatment of children at high risk for severe RSV infection who were hospitalized with proven RSV.Infants and young children younger than 2
Publikováno v:
Pediatrics. 95(4)
To evaluate the safety and efficacy of respiratory syncytial virus immune globulin (RSVIG) in the prevention of severe respiratory syncytial virus (RSV) lower respiratory tract infection (LRTI) in infants born prematurely with or without bronchopulmo
Autor:
David R. Snydman, T Hougen, H. C. Meissner, Robert L. Geggel, Gerald R. Marx, J R Groothuis, V G Hemming, David Fulton
Publikováno v:
Scopus-Elsevier
We performed a randomized, controlled trial of intravenous immune globulin (respiratory syncytial virus [RSV] neutralizing [Nt] antibody titer of 1:950 in 5% solution) to evaluate protection against RSV-induced disease over two respiratory virus seas
Publikováno v:
Journal of virology. 67(3)
Human respiratory syncytial virus (HRSV) is the most frequent cause of severe respiratory infections in infancy. No vaccine against this virus has yet been protective, and antiviral drugs have been of limited utility. Using the cotton rat model of HR
Autor:
V G, Hemming, G A, Prince
Publikováno v:
Infectious agents and disease. 1(1)